RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kuros Biosciences Stock

Kuros Biosciences ROCE 2024

Kuros Biosciences ROCE

-0.15

Ticker

KURN.SW

ISIN

CH0325814116

WKN

A2ALS5

In 2024, Kuros Biosciences's return on capital employed (ROCE) was -0.15, a 6.76% increase from the -0.14 ROCE in the previous year.

Kuros Biosciences Aktienanalyse

What does Kuros Biosciences do?

Kuros Biosciences AG is a leading Swiss biotech company specializing in the development of novel products for the regeneration of bones and soft tissues. Founded in 2004 in Zurich, the company has since experienced a remarkable history of scientific progress, partnerships, and growth. Kuros' business model is based on researching and developing innovative therapy products in the fields of orthopedics and traumatology. The company relies on proprietary technologies and products based on natural body processes and cellular signals. Kuros aims to reduce the use of autologous bone or tissue transplantation and improve patient care with this approach. The company is divided into three strategic business areas: orthobiologics, neurotherapeutics, and tissue repair. The orthobiologics area includes products for the regeneration and restoration of bone defects and injuries. Kuros has developed a novel synthetic bone matrix called MagnetOs, which supports bone growth due to its bioactive properties. The neurotherapeutics area focuses on therapy products for the treatment of neurological diseases such as strokes. Kuros utilizes its expertise in cellular signaling to develop targeted and effective therapies. The third business area, tissue repair, concentrates on the development of products for the repair of soft tissues and tendons. The company has created a variety of innovative solutions based on the body's own regeneration processes in this area. Research and development are at the center of Kuros' business model as a biotech company. The company aims to continually develop new products and therapy solutions to improve patient care in the fields of orthopedics, neurology, and tissue repair. Within this framework, Kuros closely collaborates with leading scientific institutions and partners from the pharmaceutical and medtech industries. Overall, Kuros Biosciences has developed an impressive range of products based on the latest scientific knowledge, offering comprehensive solutions for the regeneration of bones, soft tissues, and nerve cells. Kuros' core business lies in the targeted marketing and distribution of these products to medical professionals and clinics. Since its founding in 2004, Kuros Biosciences AG has experienced an exciting history of progress and growth. With an innovative business model, a strong focus on research and development, and a wide range of products, the company has established itself as a key player in the biotech industry. Kuros' success is based on close collaboration with leading scientists and partners, as well as a strong commitment to meeting the needs of patient care and medical professionals. Kuros Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Kuros Biosciences's Return on Capital Employed (ROCE)

Kuros Biosciences's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Kuros Biosciences's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Kuros Biosciences's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Kuros Biosciences’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Kuros Biosciences stock

What is the ROCE (Return on Capital Employed) of Kuros Biosciences this year?

The ROCE of Kuros Biosciences is -0.15 undefined this year.

How has the ROCE (Return on Capital Employed) of Kuros Biosciences developed compared to the previous year?

The ROCE of Kuros Biosciences has increased by 6.76% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Kuros Biosciences?

A high Return on Capital Employed (ROCE) indicates that Kuros Biosciences has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Kuros Biosciences?

A low ROCE (Return on Capital Employed) can indicate that Kuros Biosciences has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Kuros Biosciences impact the company?

An increase in the ROCE of Kuros Biosciences can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Kuros Biosciences affect the company?

A decrease in ROCE of Kuros Biosciences can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Kuros Biosciences?

Some factors that can affect Kuros Biosciences's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Kuros Biosciences so important for investors?

The ROCE of Kuros Biosciences is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Kuros Biosciences take to improve the ROCE?

To improve the ROCE, Kuros Biosciences can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Kuros Biosciences pay?

Over the past 12 months, Kuros Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kuros Biosciences is expected to pay a dividend of 0 CHF.

What is the dividend yield of Kuros Biosciences?

The current dividend yield of Kuros Biosciences is .

When does Kuros Biosciences pay dividends?

Kuros Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kuros Biosciences?

Kuros Biosciences paid dividends every year for the past 0 years.

What is the dividend of Kuros Biosciences?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kuros Biosciences located?

Kuros Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kuros Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kuros Biosciences from 11/17/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did Kuros Biosciences pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of Kuros Biosciences in the year 2023?

In the year 2023, Kuros Biosciences distributed 0 CHF as dividends.

In which currency does Kuros Biosciences pay out the dividend?

The dividends of Kuros Biosciences are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kuros Biosciences

Our stock analysis for Kuros Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kuros Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.